CLL is a slowgrowing blood cancer. While it can’t be cured, many people can live well for long periods with the right treatment. Pharmac estimates around 110 people each year will benefit from the new ...

As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...

From May 1, people with chronic lymphocytic leukaemia will be able to access combination treatments of venetoclax with either ...

Time-limited venetoclax–obinutuzumab was the predominant first-line regimen, while continuous BTK inhibitor therapy remained nearly as common, and chemoimmunotherapy was rarely selected. Enrichment ...

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of ...

Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.

As artificial intelligence (AI) tools continue to proliferate, they are becoming a go-to search tool for patients, providers, ...

Q4 2025 Earnings Call March 25, 2026 8:30 AM EDTCompany ParticipantsJisong Cui - Co-Founder, Chairwoman & CEOXin Fu ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025.

The Chinese biopharmaceutical company achieved profitability milestone in its full-year financial performance driven by drug sales growth.